AAP IMPLANTATE AG O.N. overview

EQS-News: aap Implantate AG / Key word(s): Quarter Results/Development of Sales aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024 22.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Sales increase by 5.6% compared to the same quarter of the previous year Major order and parts of Q1 sales form strong basis for growth in Q2 Human clinical trial of the innovative...

EQS-News: aap Implantate AG / Key word(s): Capital Increase aap successfully places a 10% capital increase from authorized capital at EUR 1.10 with exclusion of subscription rights 19.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. The premium to the current share price of EUR 0.8 amounted to 37.5% The cash inflow will strengthen the company's own resources for the ongoing human clinical trial of the innovative antibacterial implant technology aap...

EQS-Ad-hoc: aap Implantate AG / Key word(s): Annual Report aap Implantate AG: aap postpones publication of the consolidated financial statements 2023 due to staff shortages 17-Apr-2024 / 18:57 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information in accordance with Article 17 of Regulation...

EQS-News: aap Implantate AG / Key word(s): Financing aap 100% approval of the proposed resolution to amend the terms and conditions of the mandatory convertible bond 2023/2028 03.04.2024 / 17:35 CET/CEST The issuer is solely responsible for the content of this announcement. 86.03% of the nominal amount and the votes of all outstanding bonds participated in the vote Approval by 100% of the votes cast aap Implantate AG (" aap " or "Company") successfully completed the vote without a meeting of...

EQS-Ad-hoc: aap Implantate AG / Key word(s): Capital Increase aap Implantate AG: Capital increase from authorized capital with exclusion of subscription rights 18-March-2024 / 12:35 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014...

EQS-Ad-hoc: aap Implantate AG / Key word(s): Bond aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier 05-March-2024 / 12:18 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. aap...

EQS-News: aap Implantate AG / Key word(s): Interim Report/Corporate Action After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year 15.02.2024 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. Silver: significant acceleration in patient recruitment with over 130 patients as of the end of January 2024. Sales: very good start to the 2024 financial year Start of MDR certification In the past financial year, aap Implantate AG (" aap...

EQS-Media / 10.01.2024 / 07:30 CET/CEST With regard to its innovative antibacterial implant technology, aap was able to successfully accelerate recruitment in the ongoing human clinical trial with the adapted study design in the course of 2023 and has already successfully recruited more than 100 patients by 31 December 2023. aap currently assumes that the recruitment phase will be completed as planned in the course of 2024, involving up to 14 clinical trial centers. Further successful...